|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sundar S, Neal RD and Kehoe S: Diagnosis
of ovarian cancer. BMJ. 351(h4443)2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sabini C, Sorbi F, Cunnea P and Fotopoulou
C: Ovarian cancer stem cells: Ready for prime time? Arch Gynecol
Obstet. 301:895–899. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lee JY, Yoon JK, Kim B, Kim S, Kim MA, Lim
H, Bang D and Song YS: Tumor evolution and intratumor heterogeneity
of an epithelial ovarian cancer investigated using next-generation
sequencing. BMC Cancer. 15(85)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Schwarz RF, Ng CK, Cooke SL, Newman S,
Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ, et
al: Spatial and temporal heterogeneity in high-grade serous ovarian
cancer: A phylogenetic analysis. PLoS Med.
12(e1001789)2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bai H, Li H, Li W, Gui T, Yang J, Cao D
and Shen K: The PI3K/AKT/mTOR pathway is a potential predictor of
distinct invasive and migratory capacities in human ovarian cancer
cell lines. Oncotarget. 6:25520–25532. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Luo S, Zhang Y, Yang Y, Zhu S, Liu W, Zhu
J, Liang X, Jiang Z, Sun S, Hou X, et al: Clonal tumor mutations in
homologous recombination genes predict favorable clinical outcome
in ovarian cancer treated with platinum-based chemotherapy. Gynecol
Oncol. 158:66–76. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Castellarin M, Milne K, Zeng T, Tse K,
Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH and Holt RA: Clonal
evolution of high-grade serous ovarian carcinoma from primary to
recurrent disease. J Pathol. 229:515–524. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bhardwaj BK, Thankachan S, Venkatesh T and
Suresh PS: Liquid biopsy in ovarian cancer. Clin Chim Acta.
510:28–34. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Asante DB, Calapre L, Ziman M, Meniawy TM
and Gray ES: Liquid biopsy in ovarian cancer using circulating
tumor DNA and cells: Ready for prime time? Cancer Lett. 468:59–71.
2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tuaeva NO, Falzone L, Porozov YB, Nosyrev
AE, Trukhan VM, Kovatsi L, Spandidos DA, Drakoulis N, Kalogeraki A,
Mamoulakis C, et al: Translational application of circulating DNA
in oncology: Review of the last decades achievements. Cells.
8(1251)2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sorenson GD, Pribish DM, Valone FH, Memoli
VA, Bzik DJ and Yao SL: Soluble normal and mutated DNA sequences
from single-copy genes in human blood. Cancer Epidemiol Biomarkers
Prev. 3:67–71. 1994.PubMed/NCBI
|
|
15
|
Zhou S, Xu B, Qi L, Zhu D, Liu B and Wei
J: Next-generation sequencing reveals mutational accordance between
cell-free DNA from plasma, malignant pleural effusion and ascites
and directs targeted therapy in a gastric cancer patient. Cancer
Biol Ther. 20:15–20. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Barbosa A, Peixoto A, Pinto P, Pinheiro M
and Teixeira MR: Potential clinical applications of circulating
cell-free DNA in ovarian cancer patients. Expert Rev Mol Med.
20(e6)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wyatt AW, Annala M, Aggarwal R, Beja K,
Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, et al:
Concordance of circulating tumor DNA and matched metastatic tissue
biopsy in prostate cancer. J Natl Cancer Inst.
109(djx118)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xie F, Zhang Y, Mao X, Zheng X, Han-Zhang
H, Ye J, Zhao R, Zhang X and Sun J: Comparison of genetic profiles
among primary lung tumor, metastatic lymph nodes and circulating
tumor DNA in treatment-naïve advanced non-squamous non-small cell
lung cancer patients. Lung Cancer. 121:54–60. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Xu B, Shan G, Wu Q, Li W, Wang H, Li H,
Yang Y, Long Q and Zhao P: Concordance of genomic alterations
between circulating tumor DNA and matched tumor tissue in Chinese
patients with breast cancer. J Oncol. 2020(4259293)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Imperial R, Nazer M, Ahmed Z, Kam AE,
Pluard TJ, Bahaj W, Levy M, Kuzel TM, Hayden DM, Pappas SG, et al:
Matched whole-genome sequencing (WGS) and whole-exome sequencing
(WES) of tumor tissue with circulating tumor DNA (ctDNA) analysis:
Complementary modalities in clinical practice. Cancers (Basel).
11(1399)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wan R, Wang Z, Lee JJ, Wang S, Li Q, Tang
F, Wang J, Sun Y, Bai H, Wang D, et al: Comprehensive analysis of
the discordance of EGFR mutation status between tumor tissues and
matched circulating tumor DNA in advanced non-small cell lung
cancer. J Thorac Oncol. 12:1376–1387. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Liu HE, Vuppalapaty M, Wilkerson C, Renier
C, Chiu M, Lemaire C, Che J, Matsumoto M, Carroll J, Crouse S, et
al: Detection of EGFR Mutations in cfDNA and CTCs, and comparison
to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients.
Front Oncol. 10(572895)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kidess-Sigal E, Liu HE, Triboulet MM, Che
J, Ramani VC, Visser BC, Poultsides GA, Longacre TA, Marziali A,
Vysotskaia V, et al: Enumeration and targeted analysis of KRAS,
BRAF and PIK3CA mutations in CTCs captured by a label-free
platform: Comparison to ctDNA and tissue in metastatic colorectal
cancer. Oncotarget. 7:85349–85364. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Beije N, Helmijr JC, Weerts MJA, Beaufort
CM, Wiggin M, Marziali A, Verhoef C, Sleijfer S, Jansen MPHM and
Martens JWM: Somatic mutation detection using various targeted
detection assays in paired samples of circulating tumor DNA,
primary tumor and metastases from patients undergoing resection of
colorectal liver metastases. Mol Oncol. 10:1575–1584.
2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Chimonidou M, Strati A, Malamos N, Kouneli
S, Georgoulias V and Lianidou E: Direct comparison study of DNA
methylation markers in EpCAM-positive circulating tumour cells,
corresponding circulating tumour DNA, and paired primary tumours in
breast cancer. Oncotarget. 8:72054–72068. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhang Y, Chang L, Yang Y, Fang W, Guan Y,
Wu A, Hong S, Zhou H, Chen G, Chen X, et al: Intratumor
heterogeneity comparison among different subtypes of non-small-cell
lung cancer through multi-region tissue and matched ctDNA
sequencing. Mol Cancer. 18(7)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Giannopoulou L and Lianidou ES: Liquid
biopsy in ovarian cancer. Adv Clin Chem. 97:13–71. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jagelkova M, Zelinova K, Laucekova Z,
Bobrovska M, Dankova Z, Grendar M and Dokus K: Comparison of
somatic mutation profiles between formalin-fixed paraffin embedded
tissues and plasma cell-free DNA from ovarian cancer patients
before and after surgery. Biores Open Access. 9:73–79.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Du ZH, Bi FF, Wang L and Yang Q:
Next-generation sequencing unravels extensive genetic alteration in
recurrent ovarian cancer and unique genetic changes in
drug-resistant recurrent ovarian cancer. Mol Genet Genomic Med.
6:638–647. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Han MR, Lee SH, Park JY, Hong H, Ho JY,
Hur SY and Choi YJ: Clinical implications of circulating tumor DNA
from ascites and serial plasma in ovarian cancer. Cancer Res Treat.
52:779–788. 2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6(pl1)2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mayer EL and Krop IE: Advances in
targeting Src in the treatment of breast cancer and other solid
malignancies. Clin Cancer Res. 16:3526–3532. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kim LC, Song L and Haura EB: Src kinases
as therapeutic targets for cancer. Nat Rev Clin Oncol. 6:587–595.
2009.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kang H, Jeong JY, Song JY, Kim TH, Kim G,
Huh JH, Kwon AY, Jung SG and An HJ: Notch3-specific inhibition
using siRNA knockdown or GSI sensitizes paclitaxel-resistant
ovarian cancer cells. Mol Carcinog. 55:1196–1209. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
35
|
Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M,
Zhang H, Chen SF and Yao LQ: The histone deacetylase SIRT6 inhibits
ovarian cancer cell proliferation via down-regulation of Notch 3
expression. Eur Rev Med Pharmaco. 19:818–824. 2015.PubMed/NCBI
|
|
36
|
Cohen PA, Flowers N, Tong S, Hannan N,
Pertile MD and Hui L: Abnormal plasma DNA profiles in early ovarian
cancer using a non-invasive prenatal testing platform: Implications
for cancer screening. BMC Med. 14(126)2016.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Phallen J, Sausen M, Adleff V, Leal A,
Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et
al: Direct detection of early-stage cancers using circulating tumor
DNA. Sci Transl Med. 9(eaan2415)2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lin KK, Harrell MI, Oza AM, Oaknin A,
Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, et al:
BRCA reversion mutations in circulating tumor DNA predict primary
and acquired resistance to the PARP inhibitor rucaparib in
high-grade ovarian carcinoma. Cancer Discov. 9:210–219.
2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Alves MC, Fonseca FLA, Yamada AMTD, Barros
LADR, Lopes A, Silva LCFF, Luz AS, Melo Cruz FJS and Del Giglio A:
Increased circulating tumor DNA as a noninvasive biomarker of early
treatment response in patients with metastatic ovarian carcinoma: A
pilot study. Tumour Biol. 42(1010428320919198)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE and
Choi EK: Prospective study of the efficacy and utility of TP53
mutations in circulating tumor DNA as a non-invasive biomarker of
treatment response monitoring in patients with high-grade serous
ovarian carcinoma. J Gynecol Oncol. 30(e32)2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Charo LM, Eskander RN, Okamura R, Patel
SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT and
Kurzrock R: Clinical implications of plasma circulating tumor DNA
in gynecologic cancer patients. Mol Oncol. 15:67–79.
2021.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Yang F, Tang J, Zhao Z, Zhao C and Xiang
Y: Circulating tumor DNA: A noninvasive biomarker for tracking
ovarian cancer. Reprod Biol Endocrinol. 19(178)2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Noguchi T, Iwahashi N, Sakai K, Matsuda K,
Matsukawa H, Toujima S, Nishio K and Ino K: Comprehensive gene
mutation profiling of circulating tumor DNA in ovarian cancer: Its
pathological and prognostic impact. Cancers (Basel).
12(3382)2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Salemi R, Falzone L, Madonna G, Polesel J,
Cinà D, Mallardo D, Ascierto PA, Libra M and Candido S: MMP-9 as a
candidate marker of response to BRAF inhibitors in melanoma
patients with BRAFV600E mutation detected in
circulating-free DNA. Front Pharmacol. 9(856)2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Harris FR, Kovtun IV, Smadbeck J, Multinu
F, Jatoi A, Kosari F, Kalli KR, Murphy SJ, Halling GC, Johnson SH,
et al: Quantification of somatic chromosomal rearrangements in
circulating cell-free DNA from ovarian cancers. Sci Rep.
6(29831)2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Vanderstichele A, Busschaert P, Smeets D,
Landolfo C, Van Nieuwenhuysen E, Leunen K, Neven P, Amant F, Mahner
S, Braicu EI, et al: Chromosomal instability in cell-free DNA as a
highly specific biomarker for detection of ovarian cancer in women
with adnexal masses. Clin Cancer Res. 23:2223–2231. 2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Giannopoulou L, Mastoraki S, Buderath P,
Strati A, Pavlakis K, Kasimir-Bauer S and Lianidou ES: ESR1
methylation in primary tumors and paired circulating tumor DNA of
patients with high-grade serous ovarian cancer. Gynecol Oncol.
150:355–360. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Giannopoulou L, Chebouti I, Pavlakis K,
Kasimir-Bauer S and Lianidou ES: RASSF1A promoter methylation in
high-grade serous ovarian cancer: A direct comparison study in
primary tumors, adjacent morphologically tumor cell-free tissues
and paired circulating tumor DNA. Oncotarget. 8:21429–21443.
2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Noguchi T, Sakai K, Iwahashi N, Matsuda K,
Matsukawa H, Yahata T, Toujima S, Nishio K and Ino K: Changes in
the gene mutation profiles of circulating tumor DNA detected using
CAPP-Seq in neoadjuvant chemotherapy-treated advanced ovarian
cancer. Oncol Lett. 19:2713–2720. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Paracchini L, Beltrame L, Grassi T,
Inglesi A, Fruscio R, Landoni F, Ippolito D, Delle Marchette M,
Paderno M, Adorni M, et al: Genome-wide copy-number alterations in
circulating tumor DNA as a novel biomarker for patients with
high-grade serous ovarian cancer. Clin Cancer Res. 27:2549–2559.
2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Sidaway P: Prostate cancer: Mutations in
ctDNA reflect features of metastatic disease. Nat Rev Clin Oncol.
14(526)2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
ctDNA is a specific and sensitive
biomarker in multiple human cancers. Cancer Discov.
4(OF8)2014.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218.
2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Thierry AR, El Messaoudi S, Gahan PB,
Anker P and Stroun M: Origins, structures, and functions of
circulating DNA in oncology. Cancer Metast Rev. 35:347–376.
2016.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Mouliere F and Thierry AR: The importance
of examining the proportion of circulating DNA originating from
tumor, microenvironment and normal cells in colorectal cancer
patients. Expert Opin Biol Ther. 12 (Suppl 1):S209–S215.
2012.PubMed/NCBI View Article : Google Scholar
|
|
56
|
ctDNA reveals targetable alterations.
Cancer Discov. 10(OF4)2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Franczak C, Filhine-Tressarieu P, Broséus
J, Gilson P, Merlin JL and Harlé A: Clinical interest of
circulating tumor DNA in oncology. Arch Med Res. 49:297–305.
2018.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Falzone L, Scandurra G, Lombardo V,
Gattuso G, Lavoro A, Distefano AB, Scibilia G and Scollo P: A
multidisciplinary approach remains the best strategy to improve and
strengthen the management of ovarian cancer (Review). Int J Oncol.
59(53)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Dondi G, Coluccelli S, De Leo A, Ferrari
S, Gruppioni E, Bovicelli A, Godino L, Coadă CA, Morganti AG,
Giordano A, et al: An analysis of clinical, surgical, pathological
and molecular characteristics of endometrial cancer according to
mismatch repair status. A multidisciplinary approach. Int J Mol
Sci. 21(7188)2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Heudel PE, Devouassoux-Shisheboran M,
Taieb S, Genestie C, Selle F, Morice P, Rouzier R and Ray-Coquard
I: Multidisciplinary management of advanced ovarian cancer for an
optimal therapeutic strategy. Eur J Gynaecol Oncol. 38:175–180.
2017.PubMed/NCBI
|
